Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gastrointestinal 1

Conditions

Weight Loss 1Tumor Surgery 1Obesity 1Intermittent Fasting 1Colorectal Neoplasms 1

Interventions

Bevacizumab 25Fluorouracil 23Leucovorin 22Cetuximab 22Oxaliplatin 19pembrolizumab 14Specimen Handling 12Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8Biopsy 8atezolizumab 6fludarabine 5encorafenib 5Pemetrexed 5Panitumumab 5HMPL-013 5Gemcitabine 5Folfox protocol 5Cisplatin 5Carboplatin 5trifluridine tipiracil drug combination 4balstilimab 4Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4regorafenib 3fludarabine phosphate 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Caloric Restriction × 30 days × Clear all
NCT05114798 2026-05-22

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

University of Illinois at Chicago

Phase NA Active not recruiting
193 enrolled
GastrointestinalOther

Intermittent Fasting, Obesity, Colorectal Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡